About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 2/3NCT04787471

Corneal Crosslinking for Treatment of Corneal Neovascularization

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Lead sponsor: Price Vision Group•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Marianne Price, PhD

CONTACT

317-814-2990 mprice@cornea.org

Sponsors

Lead Sponsor

Price Vision Group

Collaborators

Cornea Research Foundation of America

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•18 years of age or older
•With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
•Signed written informed consent.

Exclusion Criteria

•Known sensitivity to treatment medications
•Current condition that in the investigator's opinion could compromise safety or data integrity.
•Pregnancy (including plan to become pregnant) or lactation during the course of the study

Related studies

COMPLETEDPhase 2/3

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

NCT00555594 · Corneal Neovascularization

Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

NCT05659940 · Corneal Neovascularization, Neutrophils

COMPLETEDPhase 1

Topical Avastin for Treatment of Corneal Neovascularization

NCT00559936 · Corneal Neovascularization

TERMINATEDPhase 1/2

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

NCT02797704 · Corneal Neovascularization

COMPLETEDPhase 1/2

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

NCT01072357 · Corneal Neovascularization, Corneal Graft Failure

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 31, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2/PHASE3

Enrollment62

Start dateMay 2021

Last updatedJul 31, 2025

Condition

Corneal Neovascularization

Locations shown

Price Vision Group

Indianapolis, Indiana

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2025Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions